The COVID-19 pandemic remains uncontrolled despite the rapid rollout of safe and effective
SARS-CoV-2 vaccines, underscoring the need to develop highly effective antivirals. In the …

The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …

Remdesivir is an antiviral approved for COVID-19 treatment, but its wider use is limited by
intravenous delivery. An orally bioavailable remdesivir analog may boost therapeutic benefit …

While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent
nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir …

COVID-19 patients with severe symptoms still lack antiviral treatment options. Although
remdesivir is the only FDA-approved drug for those patients, its efficacy is limited by …

Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury®)
remains contentious. We previously pointed out pharmacokinetic, pharmacodynamic and …

The outbreak of coronavirus disease 2019 (COVID-19) has resulted in a global pandemic
due to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the
COVID-19 pandemic, has infected over 260 million people over the past 2 years. Remdesivir …

Remdesivir was the first antiviral drug to be approved for the treatment of severe COVID-19;
followed by molnupiravir (another prodrug of a nucleoside analogue) and the protease …

Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for
the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 …